Acadian Asset Management
ZVRA icon

Acadian Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Acadian Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-149,637
Closed -$1.34M – 2279
2025
Q4 		$1.34M Buy
149,637
+68,067
+83% +$644K ﹤0.01% 1030
2025
Q3 		$774K Buy
+81,570
New +$818K ﹤0.01% 1118
2020
Q3 		– Sell
-7,314
Closed -$34K – 2384
2020
Q2 		$34K Buy
+7,314
New +$29.3K ﹤0.01% 2014

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Acadian Asset Management's ZVRA Position: Q1 2026 in Review

Acadian Asset Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 149,637 shares — an estimated $1.34M sold.

Acadian Asset Management first reported a position in ZVRA in Q2 2020 and held it in 3 quarters. The position peaked at $1.34M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Acadian Asset Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 149,637 Zevra Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Acadian Asset Management first reported a position in Zevra Therapeutics in Q2 2020 and held it in 3 quarters.
  • Acadian Asset Management's Zevra Therapeutics position peaked at $1.34M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.